These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34491783)

  • 1. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.
    Jeong AY; Schwartz EB; Roman AR; McDevitt RL; Oerline MK; Henry E; Veenstra CM; Caram MEV
    JCO Oncol Pract; 2022 Feb; 18(2):e284-e292. PubMed ID: 34491783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.
    Chehrazi-Raffle A; Dorff TB
    JCO Oncol Pract; 2022 Feb; 18(2):97-98. PubMed ID: 34559572
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center.
    Farano JL; Kandah HM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):765-769. PubMed ID: 31232209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
    Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
    Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients.
    Zullig LL; Wolf S; Vlastelica L; Shankaran V; Zafar SY
    J Manag Care Spec Pharm; 2017 Apr; 23(4):407-411. PubMed ID: 28345445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Out-of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Medicare Part D Plan: An Online Tool Presents an Opportunity to Mitigate Financial Toxicity.
    Pockros B; Shabet C; Stensland K; Herrel L
    Urol Pract; 2023 Sep; 10(5):467-475. PubMed ID: 37347766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
    Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
    Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide.
    Lai LY; Oerline MK; Kaufman SR; Herrel LA; Skolarus TA; Dusetzina SB; Ellimoottil C; Shahinian VB; Hollenbeck BK; Caram MEV
    Urology; 2022 Mar; 161():50-58. PubMed ID: 34861316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer.
    Lai LY; Kaufman SR; Oerline MK; Caram MEV; Maganty A; Hollenbeck BK; Shahinian VB
    JNCI Cancer Spectr; 2022 Mar; 6(2):. PubMed ID: 35603854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
    Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
    Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV PrEP access and affordability: a multidisciplinary specialty pharmacy model.
    Whelchel K; Zuckerman AD; DeClercq J; Choi L; Rashid S; Kelly SG
    J Am Pharm Assoc (2003); 2022; 62(3):853-858. PubMed ID: 34916170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
    Goldsberry WN; Summerlin SS; Guyton A; Caddell B; Huh WK; Kim KH; Liang MI
    Gynecol Oncol; 2021 Mar; 160(3):800-804. PubMed ID: 33414026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to Effectively Decrease Patient Co-Payments of High-Cost Drugs Through Innovation: Lessons From the Karmanos Specialty Pharmacy.
    Seymour EK; Daniel L; Pointer E; Julian J; Smith ST; Schiffer CA
    JCO Oncol Pract; 2022 Jan; 18(1):e137-e151. PubMed ID: 34406816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Charity Financial Assistance for Novel Oral Anticancer Agents.
    Olszewski AJ; Zullo AR; Nering CR; Huynh JP
    J Oncol Pract; 2018 Apr; 14(4):e221-e228. PubMed ID: 29443649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?
    Pereira-Salgado A; Kwan EM; Tran B; Gibbs P; De Bono J; IJzerman M
    Eur Urol Focus; 2021 Jul; 7(4):752-763. PubMed ID: 32273196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
    Tagawa ST; Ramaswamy K; Huang A; Mardekian J; Schultz NM; Wang L; Sandin R; Lechpammer S; George DJ
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1032-1040. PubMed ID: 33612825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study on time on treatment with abiraterone and enzalutamide.
    Fallara G; Lissbrant IF; Styrke J; Montorsi F; Garmo H; Stattin P
    PLoS One; 2020; 15(12):e0244462. PubMed ID: 33370378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.
    Kulkarni AA; Rubin N; Tholkes A; Shah S; Ryan CJ; Lutsey PL; Prizment A; Rao A
    ESMO Open; 2021 Oct; 6(5):100261. PubMed ID: 34509804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.